ATP1A3 and central nervous system cancer: Finally, by using transfected U87 or U251 cells with ATP1A3 knockdown, we further performed cell viability assays to examine the effect of ATP1A3 on the anti‐glioma efficacy of CS‐6, as well as the synergistic therapeutic effect of CS‐6 and TMZ (Figure 2K).